Foundation Medicine is a global, patient-focused precision medicine company transforming lives in cancer and beyond. Founded in 2010, the company serves as an essential partner to patients, physicians, researchers, and biopharmaceutical organizations navigating the complex treatment landscape. With more experience in comprehensive genomic profiling than any company in the industry, Foundation Medicine has developed an extensive genomic database and body of research that strengthen their diagnostic solutions.
Foundation Medicine's portfolio of FDA-approved tests includes FoundationOne CDx for tissue-based companion diagnostics across all solid tumors with 35+ targeted therapy indications, FoundationOne Liquid CDx for blood-based diagnostics covering 15+ targeted therapies, and FoundationOne Heme for hematologic malignancies. Their tests are covered by all major U.S. health insurers including Aetna, Anthem, and United Healthcare. By collaborating with biopharmaceutical organizations across the entire therapy development lifecycle, Foundation Medicine accelerates the discovery and development of new personalized therapies while providing actionable insights that guide treatment decisions throughout a patient's experience.